CLINICAL TRIALS PROFILE FOR COMIRNATY

All Clinical Trials for COMIRNATY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04860739 ↗	Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose	Active, not recruiting	Instituto de Salud Carlos III	Phase 2	2021-04-24	CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA.
NCT04860739 ↗	Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose	Active, not recruiting	Spanish Clinical Research Network - SCReN	Phase 2	2021-04-24	CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA.
NCT04951323 ↗	Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)	Recruiting	Pfizer	Phase 3	2021-03-22	The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by Pfizer-BioNTech) being authorized in the European Union since December 2020. The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
NCT04951323 ↗	Impact of the Immune System on Response to Anti-Coronavirus Disease 19 (COVID-19) Vaccine in Allogeneic Stem Cell Recipients (Covid Vaccin Allo)	Recruiting	University of Liege	Phase 3	2021-03-22	The present study is a prospective phase IV study. All participants will receive the anti-Coronavirus Disease 2019 (COVID-19) Vaccine (messenger Ribonucleic acid-based vaccine, BNT162b2 or Comirnaty®, commercialized by Pfizer-BioNTech) being authorized in the European Union since December 2020. The vaccine is administered intramuscularly after dilution as a series of two doses at least 21 days apart.
NCT05077254 ↗	COVID Protection After Transplant-Immunosuppression Reduction	Not yet recruiting	PPD	Phase 2	2021-11-01	This study will enroll individuals who have: - Completed, at a minimum, a full 2-dose course of either the Moderna messenger RNA (mRNA) based coronavirus infectious disease 19 (COVID-19) vaccine or the Pfizer-BioNTech mRNA based COVID-19 vaccine, and - A negative or indeterminate (
NCT05077254 ↗	COVID Protection After Transplant-Immunosuppression Reduction	Not yet recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2021-11-01	This study will enroll individuals who have: - Completed, at a minimum, a full 2-dose course of either the Moderna messenger RNA (mRNA) based coronavirus infectious disease 19 (COVID-19) vaccine or the Pfizer-BioNTech mRNA based COVID-19 vaccine, and - A negative or indeterminate (
NCT05315362 ↗	Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine	Recruiting	Leiden University Medical Center	Phase 2	2022-05-01	COVID-19 vaccines are limited in supply, especially in low- and middle-income countries, leading to substantial morbidity and mortality. Despite the COVID-19 Vaccines Global Access (COVAX) Facility initiated by the WHO to provide vaccine access for low-income countries, probably 80% of the vaccine needs of participating countries will not be met soon. In addition, there is an increasing demand for revaccination of the population globally, because of waning immunity which will further limit vaccine supplies. Exploring dose-sparing techniques, could therefore provide the solution to immunise more people with the same vaccine stockpile. The intramuscular injection (IM) is the standard inoculation route of vaccines. However, the skin (dermis) is much richer in antigen presenting dendritic cells than muscle. As a consequence, a fractional vaccine dose introduced directly into the dermis (intradermal administration, ID) might be as effective as the intramuscular administration of the full standard dose to achieve a protective immune response. This principle has recently been demonstrated for the ID dermal delivery of one-fifth fractional dose mRNA-1273 (Spikevax, Moderna) vaccine. However, needle-based immunisation has several limitations. Fear of needles makes immunisation a stressful event. In addition, needle stick injuries, as well as unsafe injection practices carry serious health risks. Therefore, the development of needle-free delivery has been identified as an important goal in global health care. The WHO reported that microneedle vaccine delivery is top priority and requires additional research to explore the benefits in more detail. A big advantage of intradermal delivery via a solid needle patch is not only the absence of needles and pain since no nerves are at the proximity where the needles are presented, but also the local delivery close to immune cells as with the above mentioned intradermal injection enables a much lower dose as compared to IM dosing. And since with the patch a larger skin surface is involved as compared to intradermal injection, even lower doses are possibly still immunogenic. In this study, we will investigate the immunogenicity and safety in healthy volunteers of the needle-free intradermal delivery of a single fractional dose of 20µg mRNA-1273 LNP vaccine (Spikevax, Moderna) more than 3 months after primary vaccination with Comirnaty (Pfizer) vaccine and/or after having contracted COVID-19.

Clinical Trial Conditions for COMIRNATY

Condition Name

Condition Name for COMIRNATY
Intervention	Trials
Covid19	2
Diabetes Mellitus, Type 1	1
Hematopoietic Neoplasms	1
Kidney Transplant Recipients	1

Condition MeSH

Condition MeSH for COMIRNATY
Intervention	Trials
COVID-19	4
Virus Diseases	1
Diabetes Mellitus, Type 1	1
Diabetes Mellitus	1

Clinical Trial Locations for COMIRNATY

Trials by Country

Trials by Country for COMIRNATY
Location	Trials
United States	7
Spain	4
Germany	3
Belgium	2
Netherlands	1

Trials by US State

Trials by US State for COMIRNATY
Location	Trials
Georgia	1
California	1
North Carolina	1
New York	1
Maryland	1

Clinical Trial Progress for COMIRNATY

Clinical Trial Phase

Clinical Trial Phase for COMIRNATY
Clinical Trial Phase	Trials
PHASE4	1
Phase 3	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for COMIRNATY
Clinical Trial Phase	Trials
Recruiting	3
Active, not recruiting	2
Not yet recruiting	1

Clinical Trial Sponsors for COMIRNATY

Sponsor Name

Sponsor Name for COMIRNATY
Sponsor	Trials
Instituto de Salud Carlos III	2
Spanish Clinical Research Network - SCReN	2
Kinderkrankenhaus auf der Bult	1

Sponsor Type

Sponsor Type for COMIRNATY
Sponsor	Trials
Other	15
Industry	3
NIH	1

Last updated: May 3, 2026

COMIRNATY (Pfizer-BioNTech COVID-19 Vaccine): Clinical Trials Update, Market Analysis, and Projection

What clinical trials data shape COMIRNATY’s current label and development path?

COMIRNATY is a platform vaccine whose clinical evidence base is dominated by randomized phase 3 efficacy trials, immunogenicity and safety bridging studies for updated formulations, and ongoing real-world effectiveness surveillance. The program has continued across multiple antigen updates and age-group indications, with the current commercial product line governed by regulators through variant-matching and immunogenicity/safety data rather than repeating full efficacy phase 3 for every update.

Core evidence tiers

1. Initial pivotal efficacy (phase 2/3 and phase 3)
   • The pivotal dataset supporting early authorization relied on randomized, placebo-controlled trials demonstrating efficacy against symptomatic COVID-19 after a two-dose regimen.
2. Variant adaptation and updated formulations
   • Subsequent updates use immunogenicity bridging plus safety monitoring to align with circulating variants.
3. Ongoing safety and effectiveness monitoring
   • Post-authorization pharmacovigilance and effectiveness studies inform label maintenance and risk management.

Trial program examples and milestones (high level)

• Pivotal randomized efficacy trials: The early authorization evidence is rooted in phase 3 efficacy results and follow-on analyses showing durable protection patterns within the trial observation windows (time-dependent waning).
• Updated antigen clinical work: New formulations for emerging variants have been supported by immunogenicity comparisons against prior approved formulations, with safety follow-up in trial settings and managed rollout in practice.

Key takeaway for trial-to-market linkage

• COMIRNATY’s development cadence has followed a “update with immunogenicity evidence” model. That model supports continuity of supply and label updates without always restarting large-scale efficacy phase 3.

---

What market position does COMIRNATY hold, and how has pricing and demand evolved?

COMIRNATY is the dominant global branded COVID-19 vaccine product by historical revenue scale, but its market has structurally shifted from “pandemic surge” to “annualized/seasonal demand with purchasing volatility.” Demand is now driven by:

• Variant circulation and public health guidance
• Government procurement cycles (especially in large markets)
• Risk-based prioritization (older adults, comorbidities)
• Competition and national tendering strategies

Revenue scale: the definitive pattern

• COMIRNATY’s peak revenue was tied to large government contracts and broad population campaigns during earlier waves.
• As global procurement stabilized and payer budgets tightened, growth shifted from volume expansion to formulation refresh cycles and pricing/contracting discipline.

Commercial dynamics that govern current unit economics

• Government procurement dominates: tendered volumes and multi-year framework arrangements often govern purchasing.
• Price compression: increased competitive supply and normalization of spending reduced per-dose realization versus peak periods.
• Product refresh cycles: demand spikes correlate with rollout of newly updated antigens aligned to circulating strains.

---

How should forecasts be modeled for COMIRNATY through the next 3 to 5 years?

Forecasting COMIRNATY requires scenario modeling around procurement volumes, formulation updates, and competitive share. The practical forecasting framework in the COVID vaccine market is:

• Base case: continued annual/seasonal buying, with moderate volume decline versus peak and stable share depending on variant match and procurement preferences.
• Downside case: greater price pressure and reduced government purchasing intensity if COVID is downgraded further in spending priority.
• Upside case: stronger-than-expected uptake in boosters and expanded eligibility if severe waves re-emerge or payer willingness increases.

Scenario architecture (what to forecast)

• Global doses sold (or government doses distributed under contracted orders)
• Net realized price per dose (after rebates, settlements, and contract terms)
• Mix shift across age indications and formulation generations
• Country-level procurement pacing (quarterly revenue recognition patterns)
• Competitive displacement by other COVID vaccine brands and platform entrants

Projection directionality

• Volume: lower than peak, but resilient where boosters remain recommended.
• Price: typically lower than peak due to procurement normalization and competition.
• Revenue: likely to remain meaningful but structurally lower than pandemic-era highs.

---

Clinical Trial Update: What changes matter to investors right now?

Are there new clinical updates that change label or differentiation?

The label evolution for COMIRNATY is driven by regulatory approvals of updated formulations and age-group expansions based on immunogenicity and safety evidence. What changes investment-relevant outcomes is not “one new efficacy readout,” but:

• approval pathway for updated antigens
• persistence of immune response signatures across variant updates
• safety profile stability as dosing cadence shifts from mass campaigns to ongoing boosters

Why immunogenicity data is the key decision input

• For updated COVID vaccine versions, regulators use immunogenicity bridging to prior approved products as the primary evidence basis.
• That means investors should track:
  • neutralizing antibody response measures against updated strains
  • T-cell and binding antibody profiles where measured
  • safety rates of solicited and unsolicited adverse events in bridging studies
  • consistency across age cohorts

---

Market Analysis: What are the demand and supply constraints?

What drives demand for COMIRNATY in a post-peak environment?

• Policy and guidance: booster recommendations by national authorities and payers.
• Variant match: if formulation aligns with circulating strains, uptake increases.
• Cold-chain logistics and distribution: continuity of supply matters more than incremental efficacy at this stage.
• Public health confidence and acceptance: uptake can shift with perceived severity of outbreaks.

What are the main supply-side levers?

• Manufacturing scale and flexibility: ability to reconfigure lines for updated antigens.
• Regulatory batch release timing: affects quarterly shipments.
• Contract structure: take-or-pay frameworks reduce revenue volatility but may affect timing.

---

Actionable View: Investment and R&D implications

What does the COMIRNATY profile imply for next-stage R&D strategy?

• Focus shifts to incremental performance and label durability, not brand-new efficacy proof.
• Vaccine differentiation increasingly depends on:
  • antigen selection and immune durability across strains
  • safety optimization in broader age ranges
  • operational readiness for rapid seasonal or wave-driven rollouts

What does market projection imply for portfolio positioning?

• COMIRNATY likely stays a core cash generator versus smaller follow-on candidates, but growth will be capped by:
  • normalized public spending
  • pricing compression
  • procurement cycles rather than breakthrough demand

---

Key Takeaways

• COMIRNATY’s clinical evidence and ongoing development are anchored in pivotal efficacy plus immunogenicity bridging for updated formulations, with post-authorization monitoring supporting label maintenance.
• The market has moved from peak mass campaigns to annualized or seasonal procurement, creating demand volatility tied to guidance and variant circulation.
• Forecasts should be built on doses, net realized price, mix, and procurement pacing, with scenarios reflecting price pressure and uptake variability.
• The near-term investment thesis centers on label durability, updated antigen approvals, and contract execution, not repeated phase 3 efficacy resets.

---

FAQs

1. Why does COMIRNATY not require a new phase 3 efficacy trial for each update?
   Regulators generally rely on immunogenicity bridging and safety evidence to prior approved formulations, especially when the update targets variant changes rather than a wholly new vaccine concept.

2. What is the main demand driver for COMIRNATY post-pandemic?
   Booster eligibility and procurement guidance by governments and payers, plus uptake influenced by perceived outbreak severity and antigen match.

3. How should net pricing be modeled in COVID vaccine forecasts?
   Use realized price after contract terms, including rebates and settlements, and assume downward drift versus peak periods unless a contract environment tightens.

4. What outcome metrics matter most for updated COMIRNATY formulations?
   Neutralizing antibody and related immunogenicity measures against updated strains, supported by consistent safety and tolerability data across age cohorts.

5. What is the biggest uncertainty in COMIRNATY market projections?
   Future government procurement intensity and cadence, which is sensitive to policy shifts and budget priorities as COVID risk classifications evolve.

---

References

[1] FDA. Coronavirus (COVID-19) Update: FDA Takes Additional Actions to Support COVID-19 Vaccines. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements
[2] EMA. EPAR for Comirnaty. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty
[3] World Health Organization. WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/sage-roadmap-for-prioritizing-uses-of-covid-19-vaccines
[4] Pfizer. COMIRNATY (COVID-19 Vaccine, mRNA) Safety and efficacy information and press releases. https://www.pfizer.com/health/comirnaty